orforglipron
-
healthOrforglipron Pill Sustains Weight Loss After Injection Discontinuation
New trial shows oral GLP-1 orforglipron helps maintain weight loss after stopping injectable therapies tirzepatide and semaglutide.
-
healthEli Lilly’s Orforglipron Wins FDA Approval for Weight Loss
The FDA approved Eli Lilly's once-daily pill for chronic weight management in adults with obesity or related conditions.
-
healthNew GLP-1 Pill Outperforms Oral Semaglutide in Diabetes Trial
A new daily oral GLP-1 pill, orforglipron, shows superior blood glucose control compared to oral semaglutide in Type 2 diabetes patients, according to a Phase III trial.
-
healthEli Lilly's Orforglipron Shows Promise in Weight Loss Drug Race
New clinical trial results suggest Eli Lilly's orforglipron may outperform oral semaglutide in glycemic control and weight reduction for type 2 diabetes.
-
healthNew Pill Orforglipron Outperforms Ozempic in Key Diabetes and Weight Loss Trial
A groundbreaking Phase 3 trial reveals orforglipron, an oral GLP-1 drug, demonstrates superior efficacy in blood sugar control and weight reduction compared to oral semaglutide.
-
healthEli Lilly's Orforglipron Pill Shows Superior Weight Loss in Trials
New oral weight-loss drug orforglipron demonstrates significant efficacy in clinical trials, outperforming existing oral semaglutide treatments.